Lynda E. Polgreen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lynda E. Polgreen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Bradley S. Miller
Division of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, M Health Fairview Masonic Children's Hospital , Minneapolis, MN 55454
3 shared publications - Julia Steinberger
Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis (J.S.).
3 shared publications A Petryk
Department of Pediatrics, University of Minnesota, 516 Delaware Street S.E., Minneapolis, MN 55455
1 shared publicationAlan R. Sinaiko
Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA
1 shared publication- Alan R. Sinaiko
Department of Pediatrics, University of Minnesota Medical School, Minneapolis (A.R.S.).
1 shared publication - Andrew C Dietz
Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, CA, USA
1 shared publication
Latest Publications
- 8 October 2014
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 4 (4) , e89
Successful Spinal Fixation Surgery Following Teriparatide Treatment in an Adolescent Boy with Severe Osteoporosis and Progressive Kyphoscoliosis
- 8 October 2014
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 4 (4) , e89
Successful Spinal Fixation Surgery Following Teriparatide Treatment in an Adolescent Boy with Severe Osteoporosis and Progressive Kyphoscoliosis
- 1 February 2014
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 111 (2) , 101-106
Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1–2 years in children with Hurler or Hunter syndrome
- 1 February 2014
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 111 (2) , 101-106
Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1–2 years in children with Hurler or Hunter syndrome
- 1 January 2014
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 17 (1) , 200-206
Low Bone Mineral Content and Challenges in Interpretation of Dual-Energy X-Ray Absorptiometry in Children With Mucopolysaccharidosis Types I, II, and VI
- 1 January 2014
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 17 (1) , 200-206
Low Bone Mineral Content and Challenges in Interpretation of Dual-Energy X-Ray Absorptiometry in Children With Mucopolysaccharidosis Types I, II, and VI
- 19 July 2013
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 52 (12) , 1149-1153
Prevalence of Vitamin D Deficiency in International Adoptees Within the First 6 Months After Adoption
Background. Vitamin D deficiency impairs bone health and development. Objective. To determine the prevalence of and risk factors for vitamin D deficiency in pediatric international adoptees. Methods. A prospective cohort (N = 189) study from a single international adoption clinic was conducted. Total 25-hydroxy vitamin D [25(OH)D] level was measured at the initial clinical assessment (within 6 months of adoption). Vitamin D deficiency was defined as a 25(OH)D Results. Vitamin D deficiency was diagnosed in 8% and insufficiency in 27% of the cohort. Lower body mass index and longer time in an institution were associated with vitamin D deficiency and insufficiency independent of age. Conclusions. Vitamin D insufficiency was common in our cohort of international adoptees. The significance of vitamin D insufficiency on bone development during the typical “catch-up” growth following international adoption needs to be determined.
- 19 July 2013
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 52 (12) , 1149-1153
Prevalence of Vitamin D Deficiency in International Adoptees Within the First 6 Months After Adoption
Background. Vitamin D deficiency impairs bone health and development. Objective. To determine the prevalence of and risk factors for vitamin D deficiency in pediatric international adoptees. Methods. A prospective cohort (N = 189) study from a single international adoption clinic was conducted. Total 25-hydroxy vitamin D [25(OH)D] level was measured at the initial clinical assessment (within 6 months of adoption). Vitamin D deficiency was defined as a 25(OH)D Results. Vitamin D deficiency was diagnosed in 8% and insufficiency in 27% of the cohort. Lower body mass index and longer time in an institution were associated with vitamin D deficiency and insufficiency independent of age. Conclusions. Vitamin D insufficiency was common in our cohort of international adoptees. The significance of vitamin D insufficiency on bone development during the typical “catch-up” growth following international adoption needs to be determined.
- Open Access
Association of Osteocalcin With Obesity, Insulin Resistance, and Cardiovascular Risk Factors in Young Adults
Low levels of osteocalcin (OCN), an osteoblast‐specific hormone, have recently been associated with insulin resistance (homeostasis model assessment‐insulin resistance (HOMA‐IR)) and obesity, particularly in older adults. The aim of this study was to determine whether low levels of OCN would be associated with insulin resistance, obesity, and greater cardiovascular (CV) risk in young adults just emerging from adolescence. Undercarboxylated OCN and carboxylated OCN levels were measured on stored serum samples (total OCN = undercarboxylated OCN + carboxylated OCN) on 137 participants (67 males) at mean age 18.6 years (range 17–22 years). Insulin resistance was measured by hyperinsulinemic—euglycemic clamp (Mlbm). Multivariable regression analyses with ln(OCN) as the independent variable were adjusted for age, sex, ethnicity, and BMI as indicated. Total OCN was inversely related to BMI, waist circumference, systolic blood pressure (SBP), interleukin (IL)‐6, and directly related to Mlbm; only SBP remained significant (with Mlbm P = 0.0560) after further adjustment for BMI. Carboxylated OCN was inversely related to BMI, waist circumference, SBP, low‐density lipoprotein cholesterol (LDL‐C), and directly related to adiponectin; SBP and adiponectin remained significant after further adjustment for BMI. There were no significant associations with undercarboxylated OCN. In summary, most associations with OCN were mediated via BMI. However, the significant associations of OCN with SBP, obesity, and adiponectin and borderline with Mlbm, suggest a potential role for OCN in the development of insulin resistance and CV risk that becomes more apparent with aging into older adulthood.
Open AccessAssociation of Osteocalcin With Obesity, Insulin Resistance, and Cardiovascular Risk Factors in Young Adults
Low levels of osteocalcin (OCN), an osteoblast‐specific hormone, have recently been associated with insulin resistance (homeostasis model assessment‐insulin resistance (HOMA‐IR)) and obesity, particularly in older adults. The aim of this study was to determine whether low levels of OCN would be associated with insulin resistance, obesity, and greater cardiovascular (CV) risk in young adults just emerging from adolescence. Undercarboxylated OCN and carboxylated OCN levels were measured on stored serum samples (total OCN = undercarboxylated OCN + carboxylated OCN) on 137 participants (67 males) at mean age 18.6 years (range 17–22 years). Insulin resistance was measured by hyperinsulinemic—euglycemic clamp (Mlbm). Multivariable regression analyses with ln(OCN) as the independent variable were adjusted for age, sex, ethnicity, and BMI as indicated. Total OCN was inversely related to BMI, waist circumference, systolic blood pressure (SBP), interleukin (IL)‐6, and directly related to Mlbm; only SBP remained significant (with Mlbm P = 0.0560) after further adjustment for BMI. Carboxylated OCN was inversely related to BMI, waist circumference, SBP, low‐density lipoprotein cholesterol (LDL‐C), and directly related to adiponectin; SBP and adiponectin remained significant after further adjustment for BMI. There were no significant associations with undercarboxylated OCN. In summary, most associations with OCN were mediated via BMI. However, the significant associations of OCN with SBP, obesity, and adiponectin and borderline with Mlbm, suggest a potential role for OCN in the development of insulin resistance and CV risk that becomes more apparent with aging into older adulthood.
- Open Access
- 28 March 2012
- Published by Springer Nature in BMC Pediatrics
- Vol. 12 (1) , 40
Modifiable risk factors associated with bone deficits in childhood cancer survivors
To determine the prevalence and severity of bone deficits in a cohort of childhood cancer survivors (CCS) compared to a healthy sibling control group, and the modifiable factors associated with bone deficits in CCS.
- 28 March 2012
- Published by Springer Nature in BMC Pediatrics
- Vol. 12 (1) , 40
Open AccessModifiable risk factors associated with bone deficits in childhood cancer survivors
To determine the prevalence and severity of bone deficits in a cohort of childhood cancer survivors (CCS) compared to a healthy sibling control group, and the modifiable factors associated with bone deficits in CCS.
- Open Access
- 1 January 2010
- Published by SAGE Publications in Journal of Pediatric Rehabilitation Medicine
- Vol. 3 (1) , 25-38
Growth patterns and the use of growth hormone in the mucopolysaccharidoses
Short stature is characteristic of patients with mucopolysaccharidosis (MPS) diseases. For children with skeletal dysplasias, such as MPS, it is important to know the natural history of growth. An understanding of the natural growth pattern in each MPS disease provides a measurement to which treatments can be compared, as well as data which can help families and providers make individualized decisions about growth promoting treatments. Multiple advancements have been made in the treatment of MPS with both hematopoietic cell transplantation (HCT) and enzyme replacement therapy (ERT). The long term benefit of these treatments on growth is unknown. This article will review the published data on growth in children with MPS, and describe preliminary data on the use of human growth hormone (hGH) in children with MPS.
- 1 January 2010
- Published by SAGE Publications in Journal of Pediatric Rehabilitation Medicine
- Vol. 3 (1) , 25-38
Open AccessGrowth patterns and the use of growth hormone in the mucopolysaccharidoses
Short stature is characteristic of patients with mucopolysaccharidosis (MPS) diseases. For children with skeletal dysplasias, such as MPS, it is important to know the natural history of growth. An understanding of the natural growth pattern in each MPS disease provides a measurement to which treatments can be compared, as well as data which can help families and providers make individualized decisions about growth promoting treatments. Multiple advancements have been made in the treatment of MPS with both hematopoietic cell transplantation (HCT) and enzyme replacement therapy (ERT). The long term benefit of these treatments on growth is unknown. This article will review the published data on growth in children with MPS, and describe preliminary data on the use of human growth hormone (hGH) in children with MPS.
- 2 March 2009
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 44 (5) , 279-285
Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation
- 2 March 2009
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 44 (5) , 279-285
Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation